Beijing’s Yisheng Biopharma has dosed the first patient in a Phase I trial of its lead drug candidate, an immuno-oncology product aimed at treating solid tumor cancers. YS-ON-001 has multiple immuno-modulating mechanisms, according to the company. In the US, the FDA granted YS-ON-001 orphan drug designation as a treatment for hepatocellular carcinoma last year. Yisheng develops vaccines and oncology drugs, all of which are based on its proprietary PIKA adjuvant technology.
